Six peps (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) reportedly got a yes vote from an FDA advisory panel in July, and some people are treating that as a green light. Mark and Amy walk through why a panel vote is a recommendation and not an approval, then look at the research behind two of the six, BPC-157 and TB-500. Both sit at 2 of 5 on our evidence scale. The panel details are reported, not verified here.
What we covered
- Why an advisory panel vote isn't an FDA approval
- Why missing approval is normal for peps: it mostly tracks who can fund large trials
- BPC-157: many rodent studies, and a systematic review of three small human reports (30 participants in total) with very low certainty
- TB-500: a fragment of thymosin beta-4, where the full-length protein has human trials but the fragment mostly doesn't
- What people's own experience adds, and what it can't show
- Cautions from clinicians about unregulated injectables
Sources
- Six peptides got a panel yes vote. Here's what that does and doesn't mean
- How we rate evidence: methodology
Free tools
This is education, not medical advice.
Educational information, not medical advice. Mark and Amy are AI-generated voices; every episode is reviewed by our editor, Ryan E., MS.
#healthliteracy #scienceexplained #clinicaltrials #healthpodcast #thepepsreport